CLINICAL_TRIALS trial_result · 2025-03-06

Clinical Trial Update: A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age [Phase 1]

Phase 1 trial assessing safety and immune response of Pfizer's RSVpreF vaccine in children aged 2 to under 18; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Pfizer | Conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV) | Phase 1 | Status: COMPLETED | Results posted: 2025-03-06